Development of an adjuvanted nanoparticle vaccine against influenza virus, an in vitro study.
Influenza is an infectious respiratory illness caused by influenza viruses. Despite yearly updates, the efficacy of influenza vaccines is significantly curtailed by the virus antigenic drift and antigenic shift. These constant changes to the influenza virus make-up also challenge the development of...
Main Authors: | Kamonthip Rungrojcharoenkit, Panya Sunintaboon, Damon Ellison, Louis Macareo, Panuwat Midoeng, Preamrudee Chaisuwirat, Stefan Fernandez, Sukathida Ubol |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0237218 |
Similar Items
-
Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.
by: Taweewun Hunsawong, et al.
Published: (2015-09-01) -
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
by: Tuksin Jearanaiwitayakul, et al.
Published: (2021-07-01) -
Dengue: An Emerging Health Challenge ?
by: Sukathida Ubol
Published: (2007-07-01) -
Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus
by: Daiki Nagatomo, et al.
Published: (2015-01-01) -
Influenza virus seroincidence in a cohort of healthy and high-risk children enrolled in infancy, Bangkok, Thailand
by: Kamonthip Rungrojcharoenkit, et al.
Published: (2019-12-01)